Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5796261 | 1.00 | HTT (0.56) | HTTMEN1KMT2ASLC22A6SLC22A8 | |
| SCHEMBL2211645 | 0.89 | HTT (0.56) | HTTMEN1KMT2ASLC22A6SLC22A8 | |
| SCHEMBL2215802 | 0.85 | HTT (0.52) | HTTMEN1KMT2ASLC22A6SLC22A8 | |
| SCHEMBL2208985 | 0.78 | HTT (0.56) | HTTMEN1KMT2ASLC22A6SLC22A8 | |
| Apocynin SCHEMBL28537029 | 0.76 | HTT (0.71) | HTTMEN1KMT2ASLC22A6SLC22A8 | |
| SCHEMBL1491848 | 0.76 | MEN1 (0.68) | HTTMEN1KMT2ASLC22A6SLC22A8 | |
| SCHEMBL5597481 | 0.74 | HTT (0.59) | HTTMEN1KMT2ASLC22A6SLC22A8 | |
| SCHEMBL5597482 | 0.74 | HTT (0.59) | HTTMEN1KMT2ASLC22A6SLC22A8 | |
| Apocynin SCHEMBL108512 | 0.74 | HTT (0.73) | HTTMEN1KMT2ASLC22A6SLC22A8 | |
| SCHEMBL760262 | 0.74 | MEN1 (0.82) | HTTMEN1KMT2ASLC22A6SLC22A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006052985-A1 | LACTONES AS NEW OXYGENATE FUEL ADDITIVES, FUELS BASED THEREON AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-05-18 | — | — | WO | claimed |
| US-20060096158-A1 | Lactones as new oxygenate fuel additives, fuels based thereon and methods for using same | ROBINSON J M | 2006-05-11 | — | — | US | claimed |
| US-5877210-A | CONTROLLING IMMUNE RESPONSE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | claimed |
| US-5583242-A | VANADYL COMPLEXES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | claimed |
| US-5565491-A | FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | claimed |
| US-20230241078-A1 | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | CFM PHARMA HOLDING B.V. (NL) | 2023-08-03 | — | — | US | disclosed |
| US-20200246352-A1 | Vanadyl and vanadate for use in reducing stress-induced metabolic derangement | CFM PHARMA HOLDING B.V. (NL) | 2020-08-06 | — | — | US | disclosed |
| EP-3684352-A1 | VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT | CFM Pharma Holding BV (NL) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019059770-A1 | VANADYL AND VANADATE FOR USE IN REDUCING STRESS -INDUCED METABOLIC DERANGEMENT | CFM PHARMA HOLDING B.V. (NL) | 2019-03-28 | — | — | WO | disclosed |
| WO-2006052985-A1 | LACTONES AS NEW OXYGENATE FUEL ADDITIVES, FUELS BASED THEREON AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060096158-A1 | Lactones as new oxygenate fuel additives, fuels based thereon and methods for using same | ROBINSON J M | 2006-05-11 | — | — | US | disclosed |
| US-5877210-A | CONTROLLING IMMUNE RESPONSE | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| US-5846998-A | Use of phosphotyrosine phosphatase inhibitors or phosphotyrosine kinase activators for controlling cellular proliferation | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-12-08 | — | — | US | disclosed |
| US-5693627-A | TREATING DISEASES SUCH AS LEUKEMIAS AND LYMPHOMAS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5583242-A | VANADYL COMPLEXES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| US-5565491-A | FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0735880-A1 | USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION | Bristol-Myers Squibb Company (US) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995020390-A1 | USE OF VANADIUM MOLYBDENUM OR TUNGSTEN COMPLEXES FOR CONTROLLING CELLULAR PROLIFERATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-08-03 | — | — | WO | disclosed |